0001104659-24-077834 4 1 20231117 20240703 20240703 Maccecchini Maria-Luisa 0001315018 4 34 001-39202 241100933 1223 FOXGLOVE LANE WEST CHESTER PA 19380 Annovis Bio, Inc. 0001477845 2834 03 Life Sciences 262540421 DE 1231 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 QR Pharma, Inc. 20091202 4 1 tm2417696-3_4seq1.xml OWNERSHIP DOCUMENT FORM 4 OMB APPROVAL ? Check this box OMB Number: if no longer 3235-0287 subject to Estimated Section 16. Form average burden 4 or Form 5 hours per obligations may response... 0.5 continue. See Instruction 1(b). ? Check this box UNITED STATES SECURITIES AND EXCHANGE COMMISSION to indicate that Washington, D.C. 20549 a transaction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF was made SECURITIES pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 1. Name and Address of Reporting 2. Issuer Name and Ticker 5. Relationship of Person * or Trading Symbol Reporting Person(s) to Maccecchini Maria-Luisa Annovis Bio, Inc. [ ANVS ] Issuer (Check all applicable) __X__ Director __X__ 10% Owner __X__ Officer (give title (Last) (First) (Middle) 3. Date of Earliest below) _____ Other C/O ANNOVIS BIO, INC., 101 Transaction (MM/DD/YYYY) (specify below) LINDENWOOD DR, SUITE 225 11/17/2023 President and CEO (Street) 4. If Amendment, Date 6. Individual or MALVERN, PA 19355 Original Filed Joint/Group Filing (Check (MM/DD/YYYY) Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More (City) (State) (Zip) than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security 2. Trans. Date 2A. 3. Trans. 4. Securities 5. Amount of 6. Ownership 7. Nature of (Instr. 3) Deemed Code Acquired (A) or Securities Form: Direct (D) Indirect Execution (Instr. 8) Disposed of (D) Beneficially or Indirect (I) Beneficial Date, if (Instr. 3, 4 and Owned Following (Instr. 4) Ownership any 5) Reported (Instr. 4) Transaction(s) (A) (Instr. 3 and 4) or Code V Amount (D) Price Common Stock (1) 3/28/2024 G 10,000 D $0 1,088,459 D Common Stock (1) 3/31/2024 G 10,000 D $0 1,078,459 D Common Stock (1) 3/31/2024 G 10,000 D $0 1,068,459 D Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 2. 3. Trans. Date 3A. 4. Trans. 5. Number of 6. Date Exercisable and 7. Title and Amount of 8. Price 9. Number of 10. 11. Nature Derivate Security Conversion Deemed Code Derivative Expiration Date Securities Underlying of derivative Ownership of (Instr. 3) or Execution (Instr. 8) Securities Acquired Derivative Security Derivative Securities Form of Indirect Exercise Date, if (A) or Disposed of (Instr. 3 and 4) Security Beneficially Derivative Beneficial Price of any (D) (Instr. 5) Owned Security: Ownership Derivative (Instr. 3, 4 and 5) Following Direct (D) (Instr. 4) Security Reported or Transaction(s) Indirect Date Expiration Amount or (Instr. 4) (I) Exercisable Date Title Number of (Instr. 4) Code V (A) (D) Shares Stock Option Common (right to $6.07 11/17/2023 A 252,000 (3) 11/17/2033 Stock 252,000 $0 252,000 D buy) (2) Stock Option Common (right to $6.07 11/17/2023 A 108,800 (5) 11/17/2033 Stock 108,800 $0 108,800 D buy) (4) Explanation of Responses: (1) Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. (2) On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. (3) Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025. (4) The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved. (5) The stock option shall vest immediately. Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Maccecchini Maria-Luisa C/O ANNOVIS BIO, INC. X X President and CEO 101 LINDENWOOD DR, SUITE 225 MALVERN, PA 19355 Signatures /s/ Maria Maccecchini 7/3/2024 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.